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Abstract: This systematic review and meta-analysis focused on randomized controlled trials (RCT) of
multinutrients consisting of at least four vitamins and/or minerals as interventions for participants
with psychiatric symptoms. A systematic search identified 16 RCTs that fit the inclusion criteria
(n = 1719 participants) in six psychiatric categories: depression, post-disaster stress, antisocial
behavior, behavioral deficits in dementia, attention-deficit/hyperactivity disorder, and autism.
Grading of Recommendations, Assessment, Development and Evaluations (GRADE) was used
to rate the evidence base. Significant clinical benefit was assessed using minimal clinically important
differences (MIDs). Due to heterogeneity in participants, multinutrient formulas, outcome measures,
and absence of complete data, only the Attention-Deficit/Hyperactivity Disorder (ADHD) category was
eligible for meta-analyses. In ADHD populations, statistically and clinically significant improvements
were found in global functioning, Mean Difference (MD) −3.3, p = 0.001, MID −3.26; Standardized
Mean Difference (SMD) −0.49 p = 0.001 MD −0.5), clinician ratings of global improvement (MD −0.58,
p = 0.001, MID −0.5) and ADHD improvement (MD −0.54, p = 0.002, MID −0.5), and clinician
(but not observer) measures of ADHD inattentive symptoms (MD −1.53, p = 0.05, MID −0.5).
Narrative synthesis also revealed a pattern of benefit for global measures of improvement, for
example: in autism, and in participants with behavioral deficits in dementia. Post-natural disaster
anxiety and the number of violent incidents in prison populations also improved. Broad-spectrum
formulas (vitamins + minerals) demonstrated more robust effects than formulas with fewer ingredients.
This review highlights the need for robust methodology-RCTs that report full data, including means
and standard deviations for all outcomes-in order to further elucidate the effects of multinutrients for
psychiatric symptoms.
Keywords: systematic review; meta-analysis; multinutrients; vitamins; minerals; psychiatric symptoms;
mood; depression; ADHD; autism
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1. Introduction
Poor nutrition is increasingly identified as a modifiable risk factor for the development and
persistence of psychiatric problems [1], with research identifying that the Western diet, high in
salt, saturated fat, ultra-processed ingredients, and sugar is most consistently associated with poor
mental health [2,3]. Interventions aimed at modifying diet and encouraging greater adherence to the
Mediterranean diet have shown success at improving mental health (e.g., anxiety and depression) for
some, but not all, study participants [4,5]. A common hypothesis across these diet improvement studies
is that nutrient density is increased through higher consumption of vegetables and fruit, and lower
consumption of ultra-processed foods.
However, a number of factors may impair an individual’s ability to fully benefit from dietary
manipulation alone: both environmental and individual variables. On the environmental front,
the depletion of essential nutrients in our food (e.g., magnesium, selenium, copper) over the last
century [6], the use of herbicides and pesticides that diminish essential nutrients in crops through
chelation of minerals [7], an emphasis on high-yield crops at the expense of nutrient density [8],
and even the increase in atmospheric CO2 [9,10] have all been identified as threats to the quality of
human nutrition and contributors to the reduced nutrient density of plants.
At the individual level, several factors may contribute to the need for more nutrients than what
might be available in one’s diet, even if characterized as a “healthy” diet. These factors include poor
gut health and microbiome composition [11–13], the presence of inflammation [14], genetic variation
leading to possible in-born errors of metabolism, which slow metabolic activity due to suboptimal
availability of vitamin and mineral cofactors [15], and mitochondrial dysfunction that may result in
decreased production of cellular energy in psychiatric disorders [13,16,17]. The presence of any of
these factors may effectively reduce the availability of nutrients necessary for optimal brain health.
Bearing in mind these factors, micronutrient supplementation may be a consideration beyond
diet manipulation. However, there is an ongoing debate as to whether a single or multiple ingredient
intervention is appropriate [18]. The majority of studies conducted over the last 100 years in the field
of psychology and psychiatry have focused on one nutrient in order to determine the active ingredient.
A number of systematic reviews and meta-analyses have highlighted the concentrated effort to find
the single nutrient that may alleviate symptoms associated with complex psychiatric issues such
as mood [19–21], psychosis [22], attention-deficit/hyperactivity disorder (ADHD) [23] or antisocial
behaviors [24], with most of these studies finding only modest benefit from a single nutrient approach.
Based on an improved understanding of the physiological requirements of the brain [25],
researchers are acknowledging that the search for a single nutrient to resolve complex psychiatric
symptoms is unrealistic. Instead, consuming a variety of essential minerals and vitamins in combination,
rather than single nutrients, makes physiological sense [17].
For example, multiple nutrients are required in biological processes related to optimizing
metabolic function for mental health such as the methylation and the Krebs cycles [17].
Neurotransmitter metabolism-synthesis, uptake, and breakdown-requires enzymes at each step,
and the enzymes are dependent upon multiple cofactors, most of which are a variety of vitamins
and minerals. These biological processes support the necessity of ingesting nutrients in combination
in order to optimize brain health.
The last two decades have ushered in a slow, but progressive expansion in the number of
clinical trials conducted using a broad-spectrum multinutrient approach to treat psychological
symptoms, demonstrating larger effect sizes than single nutrient studies [26,27] with the effects
consistently demonstrating a global benefit, while symptom-specific improvement has varied by the
rater (e.g., parent, teacher, and self). These broad-spectrum formulas are based on the premise that a
multinutrient approach effectively addresses the complex array of cofactor requirements for optimal
brain function. To date, there have been no systematic reviews or meta-analyses considering the strength
of the multinutrient approach in randomized controlled trials (RCTs) in a clinical population. As such,
this systematic review and meta-analysis will evaluate the scientific literature on the use of multinutrient
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and broad-spectrum multinutrients for the treatment of psychiatric symptoms. Multinutrients are
defined, for the purpose of inclusion in this paper, as formulas containing four or more ingredients:
vitamins and/or minerals, with most nutrient levels at or below Recommended Dietary Allowances
(RDAs), now referred to as Dietary Reference Intakes (DRIs). Broad-spectrum multinutrient formulas
are further delineated in this paper as containing a full complement of vitamins and essential minerals,
typically 20+ ingredients, many above RDA levels, but below upper tolerable limits (ULs) [28].
Historically, clinicians and consumers have turned to the RDA/DRI as a metric to gauge the
sufficient amount of a nutrient needed for optimal health. Developed in 1941 by the National Academy
of Medicine (formerly the Institute of Medicine (IOM) of the National Academies), the RDA/DRI is the
nutrient level determined to prevent frank deficiency in an otherwise healthy population [28]. In the
context of mental health, the RDA is not necessarily an appropriate metric, as RDA levels were not
established to account for brain health [29]. As a highly metabolically active organ, the brain may
require nutrients at levels higher than the RDA, but at doses below upper tolerable limits (ULs) or
lowest observed adverse events levels (LOAELs) [28], particularly in individuals who are experiencing
psychiatric symptoms.
2. Materials and Methods
This systematic review was prospectively registered with the National Institute for Health Research
website PROSPERO. Details of the protocol can be accessed at: www.crd.york.ac.uk/PROSPERO/
display_record.php?RecordID=79164.
2.1. Studies Included
The study selection criteria were defined before searches were completed. Only articles available
in English on RCTs were included. Searching was limited to human studies. Abstracts, letters,
and conference reports were searched for full-text references. There was no restriction on blinding.
2.2. Participants
Only studies investigating psychological or psychiatric symptoms or outcomes (e.g., acute stress,
ADHD, or depression) in humans were included in the review. The selection criteria required that
participants were admitted to this study with elevated symptoms on at least one psychological measure,
or this study required a psychiatric diagnosis or presentation (e.g., Major Depressive Disorder)
for enrollment. Trials in asymptomatic or healthy populations, or trials focused solely on improving
cognition, learning or achievement in the absence of a deficit were excluded. Trials on populations
with dementia, without externalizing or internalizing behavioral concerns (e.g., aggression, mood,
and anxiety) were excluded, as the topic area deemed was appropriate for a separate review. No other
exclusion criteria applied (e.g., population age, gender, and sample size).
2.3. Interventions
The selection criteria required that the formulas studied must consist of at least four vitamins
and/or minerals. Formulas containing botanicals, amino acids and essential fatty acids (EFAs) were
included only if part of a formula or treatment alongside at least four vitamins and/or minerals.
A minimum of four was chosen: (1) to capture, for example, the B vitamins essential for the methylation
cycle and important for brain health [30] (though studies did not have to contain four B vitamins);
(2) to measure the impact of nutrients used as a combination intervention, in contrast to an ’add
on’ to another nutrient of interest (e.g., EFAs). Formulas without complete information on specific
ingredients (including dose) were excluded (e.g., an herbal formula [31] containing vitamins did not
specify ingredients or dose). In this review, the term “multinutrients” is defined as vitamins and
minerals, given their importance as necessary cofactors for neurotransmission. No restrictions were
placed on intervention length. Studies were required to provide information on treatment responses.
Formula brand names were listed when provided.
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2.4. Comparators/Control
All control treatments were included: placebos, non-treatment controls (e.g., waitlist), and active
controls (e.g., single-nutrient supplements, medications or psychological therapies).
2.5. Outcome Measures
Only studies that used a psychological measure of psychiatric symptoms (e.g., acute stress, mood,
and anxiety) were included. Studies that used measures of cognition/cognitive decline/dementia
only (without assessing other psychological symptoms such as mood) were excluded. Studies were
included regardless of whether the psychological measure was a primary or secondary outcome
measure. As per published consensus guidelines [32], authors were inclusive in primary analyses and
then explored the sources of heterogeneity, including clinical heterogeneity in subsequent sensitivity
analyses [32]. This review’s primary outcome was a change in score on measures of psychological
symptoms (e.g., mood, anxiety, and inattention) from baseline to end of intervention period (or last
follow up).
2.6. Search Strategies for Identification of Studies
2.6.1. Electronic Searches
Relevant studies were identified through literature searches using MEDLINE, PsycINFO,
PsycARTICLES, the Cochrane Central Register of Controlled Trials (CENTRAL) and Google Scholar,
for studies published up to 31 May 2019. There was no cut-off date. The searches were conducted
using Medical Subject Headings (MeSH) terms where possible and included vocabulary related
to micronutrients (e.g., vitamin and mineral), as well as psychological or psychiatric disorders
(e.g., autism and ADHD); search strategies were adapted as appropriate for the database. See
Appendix A for specific search strategies.
2.6.2. Other Sources
To minimize publication bias, grey literature was searched. Sources including doctoral
dissertations, clinical trials registries: the Australian New Zealand Clinical Trials Registry, anzctr.org.au,
the European Union Clinical Trials Register, clinicaltrialsregister.eu, and the National Institutes of
Health, United States-based ClinicalTrials.gov were searched for any unpublished trials, and the
authors were contacted for results. Reference sections from relevant articles were examined for
additional resources and included if a study met the criteria.
2.7. Selection of Studies
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) process
was used for study selection. Study identification was conducted by two authors independently
and in duplicate (Jeanette Johnstone, Andrew Hughes); discrepancies were discussed and resolved
by consensus. Both authors read full abstracts of studies if either rater judged this study to be
potentially relevant. If doubt existed, the article was included for the next stage of evaluation. After the
screening, all remaining full-text articles were independently screened by the larger team of authors for
possible inclusion. Agreement between the raters was monitored using Covidence v2.0, Veritas Health
Innovation, Melbourne, Australia, www.covidence.org, and is reported below. Any disagreement was
resolved by discussion. The authors of this review were not blind to the authors, journals, results,
or conclusions of the included studies.
2.8. Data Extraction
Data from the included studies were extracted by a pair of reviewers independently and in duplicate
(Andrew Hughes, Amy Romijn, Jeanette Johnstone) to maximize accuracy. Coded information was
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extracted using Covidence, and included population, sample size, number of participants in each group,
intervention, control product, length of intervention period, and psychological outcome measures used.
2.9. Assessment of Methodological Quality of Included Studies
Studies were scored independently by a pair of reviewers (Andrew Hughes, Amy Romijn, Jeanette
Johnstone) using the Cochrane risk of bias tool [33] to assess risk of bias across the following domains:
sequence generation, allocation concealment, blinding of participants and personnel, blinding of
outcome assessment, incomplete outcome data, selective reporting, and other risk of bias. Any reviewer
disagreement was resolved by consensus and recorded using Covidence.
2.10. Data Synthesis and Measures of Treatment Effect
We planned to be cautious when deciding when to pool across studies due to the presumed
high level of heterogeneity inherent in this type of study design. Effect sizes were computed using
parameters taken from study reports including means and standard deviation (SD) or standard
error (SE); correlation coefficients; odds ratios (OR) or a regression coefficient with an N or 95%
Confidence Interval (CI); p-value with an N. Effect estimates for continuous outcomes were reported
using mean differences or standardized mean differences as appropriate. Because not all statistically
significant differences are large enough to be clinically meaningful, findings are presented alongside
established or estimated minimal clinically important differences (MIDs) to aid in clinical interpretability.
Published MIDs were used if available. If unavailable, authors followed published guidance and used
0.5 SD as an estimate of MIDs [34].
2.11. Missing Data
Reporting of per-protocol (completer) data, rather than intention-to-treat (ITT) data, was noted
in the narrative synthesis. Where studies did not present sufficient data and/or statistical test results
to allow for the calculation of the effect estimate, authors were contacted. When further information
was not available, the authors’ interpretation of their results was outlined in the appropriate table and
narrative synthesis, noting insufficient data to calculate effect estimates.
2.12. Assessment of the Quality of the Effect Estimate
We used the GRADE criteria to explore the certainty in the effect estimates reported in this
review. While described in detail elsewhere [35], briefly, GRADE assumes that an RCT evidence base
begins as high quality, and is ranked down as appropriate by the assessment of the following five
domains: (1) risk of bias of the included studies, (2) inconsistency in the effect estimate across studies,
(3) indirectness of the outcome measure to the outcome of interest, (4) imprecision of the summary
estimate, and (5) publication bias. GRADE rating was performed independently and in duplicate
by Joshua Goldenberg and Andrew Hughes, with disagreement resolved by consensus. Based on
published guidelines, we used formalized language to discuss the results based on the GRADE rating
and magnitude of effect [36].
3. Results
3.1. Study Selection and Inclusion
Figure 1 contains the PRISMA [37] flow diagram for study selection and inclusion. Of the
1214 abstracts screened, 16 studies met the inclusion criteria in the following six psychiatric categories:
depression, post-natural disaster stress, antisocial behaviors, behavioral issues in dementia, ADHD, and
autism; n = 1737 participants in total. Study characteristics are displayed in tabular and narrative form
and described in a narrative synthesis below. If a study was registered prior to initiation, the registration
is noted in the table. Because of the heterogeneity among study samples, nutrient formulas, and
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outcome measures, and due to unavailability of sufficient data to meta-analyze, only two studies were
included in a quantitative synthesis meta-analysis [26,27].
Figure 1. Systematic review and meta-analysis of multinutrients for psychiatric symptoms.
PRISMA (The Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram.
Of the 16 studies, one study included only women [38]; one only men [39]; four included only
children [27,40–42]; one study included adults and children [43]; and the rest only adults, both men
and women [26,44–51]. Two of the studies included participants taking adjunct medications for
depression [44,47]; the rest of the studies required participants to be off psychotropic medication.
Two studies enrolled participants with depressive symptoms plus a genetic or inflammatory marker
associated with depression [45,46]. One study added exercise and light exposure as part of the active
treatment [38]. One study used vitamin D as an active control [48]. One study pooled two groups:
a polyunsaturated fatty acids (PUFAs) plus multinutrients group with a PUFA-alone group and
compared them to placebo. The researchers compared the PUFA groups to one another [41].
3.2. Formula Ingredients
Per the inclusion criteria, studies used formulas with ≥4 ingredients; range: 6–36. All the formulas
contained vitamins B6, B9, and B12; thirteen of the formulas contained vitamin D; all the formulas
except two included minerals [45,46]; range of minerals: 1–15. Ingredients and dosages for each of the
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formulas are listed in the tables. A visual representation of the included ingredients in each study’s
formula is found in Figure 2. An over-the-counter formula, One-A-Day, is included for comparison
in Figures 2–4. In addition to differences between formula ingredients, the dosage of individual
ingredients varied widely, with nutrients at or below the RDA, and others at levels 10–50× the RDA,
but below ULs or LOAELs. For comparison across studies, the vitamin and mineral dose ranges, based
on the RDA, are shown in Figure 3. Ingredients in the formulas used in the depression studies, plus
a study of adults with ADHD, some of whom had moderate depression at baseline, are depicted in
Figure 4. Figure ?? illustrates the forest plots of the meta-analysis. Figure 6 shows dosage comparison
between formulas for magnesium and zinc, two minerals important for neurotransmission.
Figure 2. Comparing formula ingredients across studies including One-A-Day®, an over-the-counter
formula, for comparison. AminoFerr™ contains nutritive minerals to prevent iron deficiency (specific
product info. not found); intrinsic factor is a glycoprotein secreted by the stomach to aid in the
absorption of vitamin B12.
Figure 3. Comparing formula ingredient dosages of vitamins and minerals based on the Recommended
Dietary Allowance (RDA). Kaplan, 2015 a = complex B vitamin; Kaplan, 2015 b = EMP+, 4 capsules;
Rucklidge, 2012 a = EMP+, 4 capsules; Rucklidge, 2012 b = EMP+, 8 capsules; Rucklidge,
2012 c = complex B vitamins with minerals.
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Figure 4. Comparing ingredient dosages in studies of participants with depression, including
One-A-Day®, an over-the-counter formula for comparison.
3.3. Psychiatric Categories
3.3.1. Depression
Five studies investigated the impact of multinutrients on depression [38,44–47] (n = 707).
See Table 1. The patient populations in these studies ranged from those with mild to moderate depressive
symptoms [38], to adults classified with treatment-resistant Major Depressive Disorder (MDD) [47];
patients with MDD and an elevated inflammatory marker [46], or genetic polymorphism [45], and
adults with bipolar disorder and current depressive symptoms [44]. Four of the studies lasted
8 weeks [38,45–47], and one lasted 16 weeks [44]. The key outcome for depression improvement was
measured using the following instruments across the studies: the Montgomery-Asberg Depression
Rating Scale (MADRS) [52], the Beck Depression Inventory (BDI) [53], and the Center for Epidemiologic
Studies Depression Scale (CES-D) [54].
Nutrients 2020, 12, 3394 9 of 37
Table 1. Depression Studies (n = 707).
Reference Intervention-Daily Dose SampleSize Sample Characteristics Study Length Outcomes Results
Berk et al., 2019 [44]
ACTRN12612000830897
Combined Treatment (CT):
N-acetylcysteine (NAC) 2000 mg,
Acetyl L-carnitine (ALC)
1000 mg, Ubiquinone (Co Q10)
200 mg, magnesium 64 mg (as
orotate 500 mg), calcium
ascorbate dehydrate 242 mg
(equiv ascorbic acid 200 mg),
cholecalciferol 12.5µg (equiv Vit
D3 250 IU), α-tocopherol 60 IU
(equiv natural Vit E 50 IU), alpha
lipoic acid 150 mg, Retinyl
palmitate 900 µg (equiv Vit A
3000 IU), Vit H 600 µg, thiamine
hydrochloride 100 mg, riboflavin
100 mg, nicotinamide 200 mg,
calcium pantothenate 100 mg,
pyridoxine hydrochloride
100 mg, folic acid 800 µg, and
cyanocobalamin (Vit B12) 800 µg







Adults with bipolar disorder
(Diagnostic and Statistical
Manual (DSM)-IV-TR) with
current depressive episode based
on Montgomery-Asberg
Depression Rating Scale









Rating Scale (BDRS); Young








Evaluation - Range of Impaired
Functioning Tool (LIFE-RIFT),
and Quality of Life Enjoyment,
and Satisfaction Questionnaire
Short Form (Q-LES-Q)
Negative: no between group
differences at study end
(week 16)
Positive: at 4 weeks
post-continuation (week 20;
n = 32 for CT; n = 37 for placebo)
improvements were significantly
greater in the CT group
compared to placebo on the
MADRS (d = 0.53), BDRS (d =
0.50), CGI-I (d = −0.43), SOFAS
(d = −0.55), LIFE-RIFT (d = 0.53).
Authors unclear on whether
improvement reflects delayed
benefit or upon withdrawal
from intervention.
Brown et al., 2001 [38]
B1 50 mg, B6 50 mg, B2 50 mg, B9
400 µg, Se 200 µg, Vit D 400 IU
Plus: 20 min walk outside,
5 days/week, with 60% target





Adult women, with mild to
moderate depressive symptoms









Profile of Mood States (POMS),
Depression-Happiness Scale
(DHS), Rosenberg Self-Esteem




than placebo group in mood
CESD-D (d = −0.32*);
DHS (d = 0.33); self-esteem, RSE:
(d = −0.38*); and general sense of
well-being, GWB (d = 0.23).
*lower score = improvement
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Table 1. Cont.
Reference Intervention-Daily Dose SampleSize Sample Characteristics Study Length Outcomes Results
Lewis et al., 2013 [46]
Max Stress B: B1 1 mg, B2
1.6 mg, B3 30 mg, B5 3.3 mg, B6
3 mg, B9 1000 µg, B12 263 µg, B7




Adults with major depressive
disorder (MDD) or a related
depressive disorder (DSM-IV-TR





Secondary: Beck Anxiety Index
(BAI); Quality of life from the
Medical Outcomes Study Short
Form 36 (SF-36)
Unclear: improvements are
reported by the authors for the
intervention group compared to
placebo in depression on the BDI,
anxiety on the BAI, and overall
mental health on the SF-36;
however, authors also report,
“effect for time by randomization
was nonsignificant,” suggesting
no between-group differences
Mech et al., 2016 [45]
NCT02709668
EnLyte®: B9 citrated folic acid
1 mg, folinic acid 2.5 mg,
l-methylfolate magnesium 7 mg,
B1 25 µg, Flavin adenine
dinucleotide 25 µg, Pyridoxal
5′-phosphate 25 µg, B12 50 µg,
Nicotinamide adenine
dinucleotide (NADH) 25 µg,
Trimethyl glycine 500 µg,
AminoFerr TM: 1.5 mg, Vit C







Adults with MDD (DSM-5
definition) and positive for either
methylenetetra-hydrofolate
(MTHFR) C677T or A1298C
polymorphism
8 weeks Primary: MADRS
Unclear: improvements are
reported by authors for
depression on the MADRS
(d = −0.81) in intervention group
compared to placebo, however,
between-group comparisons and
M(SD) are not included in the
paper; lower homocysteine in
intervention group (d = −0.88).




800 mg, folinic acid 500 µg, Vit
B12 200 µg, Omega-3 fatty acid
concentrate (EPA-esters 1000 mg,
DHA-esters 656 mg), 5-HTP
200 mg, zinc picolinate elemental
30 mg, Vit B6 100 mg, Vit C
60 mg, magnesium amino acid
chelate, elemental 40 mg,





Adults with MDD who are
inadequately responsive to
current MDD medication and






Anxiety Rating Scale (HAMA),




Negative: placebo superior to
nutraceutical combination in
reducing MADRS scores
(d = 0.21); response rates: 51%
for the placebo and 40% for the
active intervention; remission
rates: 43% and 34% for placebo
and active groups, respectively;
no differences on other measures
ACTRN = Australian New Zealand Clinical Trials Registry Number; NCT = National Clinical Trial (US) number; Sample size n refers to the number who were included in analyses;
IU = international unit, RDA = recommended dietary allowance; Cr = chromium; P = phosphorus; Se = selenium; Mn = manganese; Cu = copper; Zn= zinc; Mg = magnesium; I = iodine;
Ca = calcium; Fe = iron; Si = silicon, silica; Cl = chloride; K = potassium; Vit A = beta-carotene, retinyl palmitate; Vit C = ascorbate, ascorbic acid; Vit D, D3 = cholecalciferol; Vit E = d-alpha
tocopheryl succinate; B1 = thiamine, B2 = riboflavin; B3 = niacin, nicotinamide; B5 = pantothenic acid, B6 = pyridoxine; B9 = folic acid, folate; Vit H = biotin; EFA = essential fatty acids;
EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; d = Cohen’s d; Primary = measure used in study for participant inclusion criteria.
Nutrients 2020, 12, 3394 11 of 37
Three studies utilized the MADRS [44,45,47]. However, heterogeneity in populations, the
inclusion criteria, and formula variations precluded meta-analysis. Berk et al., 2019 [44] enrolled
181 participants (115 included in the completer analyses) with a diagnosis of bipolar disorder who were
currently experiencing depressive symptoms and were on a stable dose of medication (antidepressant,
mood stabilizer, antipsychotic, or benzodiazepine). A statistically significant improvement was not
observed with multinutrients compared to placebo after 16 weeks, with a mean difference (MD) −0.4,
p = 0.91. However, 4 weeks post-discontinuation (20 weeks after baseline), a statistically significant
mean difference on the MADRS of −5.2 (p = 0.03) was reported in the 110 completers, which is clinically
significant, based on the estimated minimal clinically important difference (MID) (range: 1.6–1.9) [55]
Mech et al. 2016 [45] enrolled 330 participants (282 included in completer analyses) with major
depression and an identified methylenetetrahydrofolate (MTHFR) (C677T or A1298C) polymorphism.
The authors reported a mean change score difference between the multinutrient and placebo groups of
−10.7 on the MADRS, which is clinically significant based on the estimated MID (range: 1.6–1.9) [55]
(between group p-value not provided).
Sarris et al., 2019 [47] enrolled 158 participants (113 included in the completer analyses) with MDD
who were taking an antidepressant for at least 4 weeks. The observed mean difference of multinutrients
over placebo of −1.75 was not statistically significant (p = 0.33).
Two studies utilized the BDI to compare multinutrients to placebo for adults with
depressive disorders [46,47]. The populations were too heterogeneous to meta-analyze:
Lewis et al., 2013 [46] enrolled participants depressed at baseline with elevated homocysteine levels,
while Sarris et al., 2019 [47] enrolled treatment-resistant participants taking antidepressant medication.
Lewis and colleagues studied 60 adults, and although authors reported improvements in the
intervention group compared to placebo on the BDI, they also stated “effect for time by randomization
was not significant,” suggesting that multinutrients did not demonstrate a statistically significant
difference compared to placebo (MD −0.4, p-value not provided). The 113 participants studied by
Sarris et al., (2019) [47] did not demonstrate a statistically significant difference for multinutrients
compared to placebo (MD −4.4, p = 0.13).
Brown et al., (2001) [38] enrolled 104 adult women with mild to moderate depression, utilizing the
CES-D to compare multinutrients to placebo in intention-to-treat (ITT) analyses. A statistically, but not
clinically, significant difference after 8 weeks was observed (MD -3.1, p = 0.004, estimated MID = 4.0) [34].
For the outcome of clinical improvement in depression, we rated the overall quality of the evidence
base (GRADE) for multinutrients to be low. We rated down once due to inconsistency because the
effects were not consistent across studies and populations, and once for imprecision, because we
were unable to pool effect estimates across studies, and individual study estimates were imprecise.
See Table 2, GRADE-Summary of Results. Overall, multinutrients may improve symptoms in
individuals with bipolar and current depressive symptoms taking medication after 20 weeks (not
significant at 16 weeks). In women with mild to moderate depression, multinutrients may improve
symptoms slightly. In other studies (Lewis et al., 2013 [46], Mech et al., 2016 [45], Sarris et al., 2019 [47])
multinutrients may have little or no difference in outcome, though insufficient data were available to
enable exact qualification [45,46].
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Table 2. GRADE-summary of results.
Outcomes Results № of Participants(Studies)




Assessed with: MADRS, CES-D, BDI
Follow up: range 8–20 weeks
Five studies investigated the impact of multinutrients on
depressive symptoms [38,44–47]. In two studies the benefit
is unclear: one study [45] showed what appears to be a
clinically significant effect in a population with both
depression and an MTHFR genetic variant (MD = −10.7,
MID = 1.6–1.9) but provided no between-group p-value; the
second study [46] included a population with elevated
homocysteine and reported benefit on the BDI, but
statistical data did not suggest between-group differences.
Another study [38] reported a statistically, but not clinically
significant effect (MD = 3.1, p = 0.004, MID = 4).
Two studies [44,47] did not show a clinically or statistically









Follow up: range 4–6 weeks
Two studies investigated the effect of multinutrients on
post-natural disaster (flood, earthquake) symptoms of
depression, anxiety, and stress [48,49]. Both studies
compared similar multinutrient formulations to active
controls. Within group improvements were observed in
both studies across all treatment groups. The flood study
observed greater improvement over time with
multinutrients compared to vitamin D on measures of
anxiety (d = 1.08) and stress (d = 0.88), but not for
depression. While there were no significant between group
differences between two different doses of multinutrients
and the B-complex with minerals in the earthquake study,
with all three groups improving, more participants were
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Table 2. Cont.
Outcomes Results № of Participants(Studies)
Certainty of the Evidence
(GRADE)
Antisocial Behavior (Antisocial)
Assessed with: Number of disciplinary
incidents per 1000 person/days, reports
of serious offenses, violent rule
infarctions reported by prison staff,
SDAS, GHQ 28
Follow up: range 2 weeks to 9 months
Three studies measured the effect of multinutrients on
antisocial or offending behavior measured as disciplinary
incidents in incarcerated populations [39,40,50].
Two studies that were sufficiently homogeneous to
meta-analyze [39,50], reported greater improvements in the
multinutrient group vs placebo, but provided insufficient
data to perform between group comparisons. The third
study [40] investigated the effect of multinutrient
supplementation on the number of violent rule infarctions
in a population of incarcerated individuals aged 13–17.
Multinutrients demonstrated a decrease in mean rule
violations per subject of 2.85, compared to 1.63 in the
placebo arm, a difference which was statistically significant










Follow up: 12 weeks
For the outcome of behavioral issues in the context of
dementia, one study measured the effect of a multinutrient
vs placebo using the CGI-S and NPI [51]. Using the CGI-S,
this study suggests a statistically and clinically significant
effect of multinutrient supplementation in this population
(MD = −1.15, p < 0.01, MID = −1.1). However, using the
NPI instrument, the study suggests a statistically, but not
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Table 2. Cont.
Outcomes Results № of Participants(Studies)




Assessed with: CGI-I, CGI-ADHD,
CPRS, CAARS
Follow up: range 8–15 weeks
Three studies investigated the impact of multinutrients on
global and symptom improvement in patients with ADHD
[26,27,41]. One study showed benefit for two pooled
groups (multinutrients plus PUFA and PUFA-alone)
compared to placebo, but did not find group differences
between the multinutrients plus PUFA group compared to
the PUFA alone group [41]. Two studies were sufficiently
homogenous and were combined in meta-analyses [26,27].
The results showed clinically and statistically significant
improvements on global functioning SMD = −0.49, p =
0.001, clinically and statistically significant improvements
on clinician-rated global scores (MD = −0.58, p = 0.001,
MID = −0.5) and ADHD scores (MD = −0.54, p = 0.002,
MID = −0.5). Pooled analysis of clinician-rated symptom
scores showed a statistically significant improvement for
inattention (MD = 1.53, p = 0.05), but not for hyperactivity
or total scores. No effect was observed for pooled
observer-rated ADHD scores. ADHD symptom
improvement was statistically and clinically significant in
the adult study when outcome was measured by







Assessed with: Parent Global Impression
Follow up: 12 weeks
Two studies investigated clinical improvement in autism
[42,43], both used the Parent Global Impression (PGI) scale.
In children with autism, multinutrients demonstrated a
statistically and clinically significant difference compared to
placebo on the PGI sleep subscale (MD = 1.1, p = 0.03, MID
= 0.5). In children and adults with autism, multinutrients
demonstrated a statistically, but not clinically, significant
difference in PGI ratings (MD = 0.33, p < 0.01, MID = 0.5).
While the studies were adequately homogenous for pooling,







a. Inconsistent results between varying populations studied; b. Narrative synthesis was conducted, estimates are not precise; c. Considerable variation in the estimated effect between
the different study instruments and raters; d. Total population does not meet optimal information size thresholds; e. Only a single study with very few participants; f. Blinding was
broken in Zaalberg et al., 2010; g. Confidence interval is wide and includes significant improvement, no effect, and worsening of effect; h. Both studies were unblinded and had a
high risk of bias; MD = Mean Difference; MID = Minimal Clinically Important Difference; SMD = standardized mean difference; d = Cohen’s d; RCT = randomized controlled trial;
MTHFR = methylenetetrahydrofolate; MADRS = Montgomery-Asberg Depression Rating Scale; CES-D=Center for Epidemiologic Studies-Depression Scale; BDI = Beck Depression
Inventory; DASS = Depression Anxiety and Stress Scale; SDAS = Social Dysfunction and Aggression Scale; GHQ 28 = General Health Questionnaire-28; NPI = Neuropsychiatric Inventory;
CGI-S = Clinical Global Impression-Severity; CGI-I = Clinical Global Impression-Improvement; CGI-ADHD = Clinical Global Impression-ADHD; CPRS = Conners Parent Rating Scale;
CAARS = Conners Adult ADHD Rating Scale.
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3.3.2. Post-Natural Disaster Stress
Two unblinded randomized studies examined the effect of broad-spectrum multinutrients on
acute post-natural disaster stress [48,49] (n = 147, ITT analyses), with treatment ranging from 4 to
6 weeks. See Table 3.
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Kaplan et al., 2015 [48]
ANZCTR 12613001051730
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E 53.6 mg, B1 4 mg, B2 3.2 mg, B3
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µg, B12 293.2 µg, Biotin 240 µg,
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186.8 mg, I 45.2 µg, Mg 133.2 mg,
Zn 10.8 mg, Se 45.2 µg, Cu
1.6 mg, Mn 2.0 mg, Cr 138.8 µg,







bitartrate and Ginkgo biloba
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B-complex: B1 50 mg, B2 20 mg,
B3 50 mg, B5 50 mg, B6 20 mg, B7
300 µg, Folate 400 µg, B12 500 µg,
Intrinsic factor 20 mg,
or














and Stress Scale (DASS): Total
Secondary:




(CGI-I): Mood, Anxiety, Stress
subscales completed
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compared with vitamin D alone.
Micronutrient vs
vitamin D:
DASS: total (d = 0.94);
depression (d = 0.64); anxiety
(d = 1.08), stress (d = 0.88), as
reported by authors.
B-complex vs vitamin D:DASS:
total (d = 0.81); depression
(d = 0.58); anxiety (d = 0.89),





Rucklidge et al., 2012 [49]
ANZCTR12611000460909
CNETM (equivalent to EMP+TM
as above) as a “low dose”
(4 capsules)
or
a “high dose” (8 capsules)
or
1 tablet of BeroccaTM containing
Vit A 100 IU,
Vit C 1000 mg, B1 15 mg,
B2 15 mg, B3 50 mg, B6 10 mg, B9
400 µg,
B12 10 µg, B7 150 µg, B5 23 mg,
Ca 50 mg, Mg 50 mg, Zn 10 mg,















Impact of Events Scale (IES);
Perceived Stress Scale (PSS);
Traumatic Exposure Severity
Scale (TESS), modified CGI-I:
Mood, Anxiety, Stress subscales
completed by the participants




ANZCTR = Australia New Zealand Clinical Trial Registry; n refer to the number who were included in analyses; DBRCT = double-blind randomized controlled trial; IU = international
unit; RDA = recommended dietary allowance; Cr = chromium; P = phosphorus; Se = selenium; Mn = manganese; Cu = copper; Zn = zinc; Mg = magnesium; I = iodine; Ca = calcium;
Fe = iron; Si = silicon, silica; Cl = chloride; Mo = molybdenum; K = potassium; B = boron; V = vanadium; Na=sodium; Ni = nickel; Vit A = beta-carotene, retinyl palmitate; Vit C =
ascorbate, ascorbic acid; Vit D, D3 = cholecalciferol; Vit E = d-alpha tocopheryl succinate; B1 = thiamine; B2 = riboflavin; B3 = niacin, nicotinamide; B5 = pantothenic acid; B6 = pyridoxine;
B7 = biotin; B9 = folic acid, folate; Vit H = biotin; Vit K = Phytomenadione or phylloquinone; Primary = measure used in study for participant inclusion criteria.
Nutrients 2020, 12, 3394 17 of 37
Rucklidge at al., 2012 [49] included 91 adults experiencing elevated symptoms of depression,
anxiety or stress after the 2011 earthquake in Christchurch, New Zealand, while Kaplan et al., 2015 [48]
examined the impact of multinutrients in 56 adults experiencing elevated symptoms of depression,
anxiety or stress after the 2013 floods in Alberta, Canada. Both studies used the Depression Anxiety
and Stress Scale (DASS) [56] as a primary outcome measure; and for ethical reasons, both studies
used active-only control treatments, no placebo. Rucklidge [49] compared two different doses of
EMP+TM (4 or 8 capsules, daily), a broad-spectrum multinutrient formula containing 36 ingredients, to
BeroccaTM, a B complex, which also contains minerals, as an active control [49]. Kaplan et al., 2015
compared EMP+ with a B complex and used vitamin D alone as an active control [48]. Methodological
heterogeneity involving the use of all active treatments in the Rucklidge [49] study precluded
meta-analysis. Both studies reported significant within-group reductions in symptoms among all
groups in the studies. Rucklidge [49] found no significant differences between the B complex and EMP+
on primary outcomes, as measured by the DASS. However post-hoc analysis indicated that high-dose
EMP+ showed significantly greater clinical improvement over the B complex control intervention,
as measured by a modified Clinical Global Impression-Improvement rated by the participants on
subscales for mood (p < 0.05) and anxiety (p < 0.05). Kaplan [48] reported that EMP+ and B complex
were significantly more effective than the single nutrient vitamin D comparator [47]. Compared to
vitamin D, the EMP+ group had greater improvement on the DASS subscales for anxiety (d = 1.08, 95%
CI = 0.37–1.79, p < 0.05) and stress (d = 0.88, 95% CI = 0.19–1.58, p < 0.05) and the B complex group
also had greater improvement on anxiety (d = 0.89, 95% CI = 0.22–1.57, p < 0.05) and stress (d = 0.76,
95% CI = 0.10–1.43, p < 0.05).
We rated the overall quality of the evidence base (GRADE) for multinutrients for post-natural
disaster stress to be low. We rated down once for imprecision because we were unable to pool effect
estimates across studies, and individual study estimates were imprecise. We rated down once for
risk of bias as both studies were unblinded. See Table 2. Overall, multinutrients and B complex may
improve symptoms of mood, stress and anxiety following a natural disaster based on self-report,
with a possible additional benefit of multinutrients in improving mood and anxiety over B complex.
3.3.3. Antisocial Behaviors
Three studies investigated the impact of multinutrients on offending behaviors in incarcerated
populations, two in adults: Zaalberg et al., 2010 and Gesch et al., 2002 [39,50], and one in adolescents:
Schoenthaler et al., 1997 [40] (n = 445); all used completer analyses. Trial length ranged from 2 weeks
to 9 months. All three studies used a broad-spectrum multinutrient approach, with the number of
ingredients ranging from 18 to 29, provided at or above RDA levels. See Table 4.
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Gesch et al., 2002 [50]
ForcevalTM Vit A 750 µg, Vit D
10 µg, B1 1.2 mg, B2 1.6 mg, B3
18 mg, B5 4 mg, B6 2 mg, B9 400
µg, B12 3 µg, Vit C 60 mg, Vit E
10 mg, Vit K 120 µg, Vit H 100 µg,
Ca 100 mg, Fe 12 mg, Cu 2 mg,
Mg 30 mg, Zn 15 mg, I 140 µg,
Mn 3 mg, K 4 mg, P 44 mg, Se 50
µg, Cr 200 µg, Mo 250 µg; ALA
1260 mg, GLA 160 mg, EPA















Positive: Authors report the
average reduction in disciplinary
incidents was 35.1% for the
active group compared to 6.7%
for placebo group; data were
insufficient in the paper to
calculate effect sizes; authors also
report reduction in serious
offenses in active group, but not
placebo group
Schoenthaler et al., 1997 [40]
Vit A 900 µg, B1 3.6 mg, B2
3.9 mg, B3 48 mg; B5 15 mg, B6
30 mg, B7 90 µg, B9 400 µg, B12
7.2 µg, Vit C 120 mg, Vit D 5 µg,
Vit E 45 mg, Ca 122 mg, Fe 8 mg,
K 700 mg, Iodine 0.150 mg, Mg
59 mg, Zn 11 mg, Se 55 µg, Cu
0.9 mg, Mn 2.3 mg, Chromium 35
µg, Mo 45 µg, Inositol 40 mg,
Choline 40 mg, Guarana
87.78 mg, Caffeine 44 mg,









Positive: 28% fewer rule
infractions: both violent
(d = 0.52), and non-violent (d =
0.70) in those who received the
supplement than those who
received placebo
Zaalberg et al., 2010 [39]
Vit A 875 µg, B1 1.2 mg, B2
1.6 mg, B3 18 mg, B5 4 mg, B6
2 mg, B9 400 µg, B12 3 µg, Vit H
100 µg, Vit C 60 mg, Vit D3 5 µg,
Vit E 10 mg, Ca 100 mg, Mg
100 mg, P 52 mg, Zn 15 mg, Fe
12 mg, Mn 3 mg, Cu 2 mg, K
4 mg, I 140 µg, Se 50 µg, Cr 200
µg, Mo 250 µg; DHA 400 mg,
EPA 400 mg, GLA 100 mg, and 2
capsules primrose oil
n = 221
115 active 106 placebo
adult male prisoners











Positive: Authors report 34%
fewer aggressive and
rule-breaking incidents vs 14%
increase in the placebo group.
Data were insufficient to
calculate effect sizes.
Negative: No group differences
on self-reports of aggression or
psychological well-being
Sample size n refers to the number who were included in analyses; Cr = chromium; P = phosphorus; Se = selenium; Mn = manganese; Cu = copper; Zn= zinc; Mg = magnesium;
I = iodine; Ca = calcium; Fe = iron; Si = silicon, silica; Cl = chloride; Mo = molybdenum; K = potassium; B = boron; V = vanadium; Ni = nickel; Vit A = beta-carotene, retinyl
palmitate; Vit C = ascorbate, ascorbic acid; Vit D, D3 = cholecalciferol; vit E = d-alpha tocopheryl succinate; B1 = thiamine, B2 = riboflavin; B3 = niacin, nicotinamide; B5 = pantothenic acid,
B6 = pyridoxine; B9 = folic acid, folate; vit H = biotin; Vit K = Phytomenadione or phylloquinone; EFA = essential fatty acids; ALA = alpha linolenic acid, GLA = gamma linolenic acid;
EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; Primary = measure used in study for participant inclusion criteria.
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Two studies [39,50] investigated the effect of multinutrient supplementation compared to placebo
on disciplinary incidents per 1000 prison days in populations of adult prisoners (n = 393). Due to
insufficient data (lacking CIs or group percentages), studies could not be combined for meta-analysis.
Gesch [50] reported that 177 participants receiving the active intervention committed 26.3% fewer
offences (95% CI 8.3–44.3%; p = 0.03) than the placebo group, but insufficient data were provided
to calculate between group differences. Zaalberg [39] (n = 221) also reported a reduced number of
incidents in the active group (p = 0.017) and an increase in the placebo group. Zaalberg [39] reported
non-significant effects of multinutrients compared to placebo on the Social Dysfunction and Aggression
(SDAS) and the Symptom Checklist 90 (SCL-90) scales.
Schoenthaler et al., 1997 [40] investigated the effect of multinutrient supplementation on the
number of violent rule infractions in a population of incarcerated individuals (n = 62) aged 13–17.
The multinutrient group observed a decrease in mean rule violations per subject of 2.85 in the treatment
arm, compared to 1.63 in the placebo arm, a difference which was statistically significant (p = 0.005).
We rated the overall quality of the evidence base (GRADE) of multinutrients for antisocial
behaviors to be low. We rated down once for imprecision because we were unable to pool effect
estimates across studies and individual study estimates were imprecise. We rated down once for risk of
bias as blinding was broken in Zaalberg [39] and was assessed as having a high risk of bias. See Table 2.
Overall, multinutrients may improve offending behaviors in incarcerated individuals.
3.3.4. Behavioral Issues in Dementia
One study, Pardini et al., 2015 [51] investigated the use of multinutrients or placebo for the
behavioral variant of frontotemporal dementia (bv-FTD) in 26 adults, aged 50–65 years, for twelve
weeks, with a crossover to the other intervention for another 12 weeks. Participants were required
to have a previous bv-FTD diagnosis for inclusion. See Table 5. Measures included the Clinical
Global Impression-Severity (CGI-S) and the Neuropsychiatric Inventory (NPI). A statistically and
clinically significant effect of multinutrients compared to placebo was found using the CGI-S (p <
0.01, MD −1.15), which was larger than the estimated MID of 0.5 [34]. However, using the NPI
instrument, this study suggests a statistically significant, but not clinically significant effect (MD −4.70,
p < 0.01, estimated MID −8.2) [57].
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Pardini et al., 2015 [51]
SouvenaidTM: EPA




625 mg, Vit E 40 mg, Vit C
80 mg, Se 60 µg, B12 3 µg,















the Reading the Mind in the
Eyes Test (RMET)
Positive: authors report reduced
agitation, apathy, disinhibition,
and irritability on the NPI;
improvement on the CGI-S; an
increase in Theory of Mind skills
for those on active treatment;
reversal of improvement when
taken off active; insufficient data
provided to calculate effect sizes
Negative: no impact on
executive functioning on the FAB
Se = selenium; Vit C = ascorbate, ascorbic acid; vit E = d-alpha tocopheryl succinate; B6 = pyridoxine; B9 = folic acid, folate; EFA = essential fatty acids; EPA = eicosapentaenoic acid;
DHA = docosahexaenoic acid; Primary = measure used in study for participant inclusion criteria.
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We rated the overall quality of the evidence base (GRADE) to be low. We rated down twice for
imprecision as there was only a single study with very few participants (Table 2). Overall, multinutrients
may improve symptoms related to bv-FTD as measured by clinician-rated severity and may slightly
improve symptoms as measured by the NPI.
3.3.5. ADHD
Three studies investigated the impact of broad-spectrum multinutrients in populations with
ADHD: two in children [27,41] and one in adults [26]. See Table 6. Two Rucklidge studies [26,27] were
sufficiently homogenous for meta-analysis and examined global and ADHD symptom improvement
in 173 patients (80 adults, 93 children). Global assessments were measured with the Global
Assessment of Functioning (GAF) scale for adults [58], and the Children’s Global Assessment Scale
(CGAS) [59]. Global improvement was measured using the CGI-I overall and the Clinical Global
Impression-Improvement-ADHD scale (CGI-I-ADHD). ADHD symptom improvement was measured
with the Connors’ Rating Scales (CRS) and the Connors’ Adult ADHD Rating Scale (CAARS).
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Kids (Nutrients): Vit 175 IU, B1
700 µg, B2 1.1 mg, B3 12 mg, B5
2.7 mg, B6 1.3 mg, B9 100 µg, B12
1.5 µg, Vit C 60 mg, D3 100 IU,
Vit E 6 IU, Vit H 50 µg, Ca
33.9 mg, Fe 7.5 mg, Mg 8.32 mg,
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Plus: Polyunsaturated fatty acid
(PUFA): eye q™: EPA 93 mg,
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Primary: Conners Parent and Teacher
Rating Scales (CPRS), ADHD Index
Secondary: CPRS subscales:
cognitive problems/inattention,







Negative: At 15 weeks, the PUFA
group combined with the PUFA +
nutrients group showed significant
improvements over placebo for
parent ratings of inattention,
hyperactivity, and global ADHD
indices on the CPRS. PUFA +
nutrients compared to PUFA alone
showed no group differences;
authors concluded PUFA was the
primary mechanism of
improvement. However, the PUFA
+ nutrients group was not
compared to placebo. No changes
reported on the teachers
rating scales.
ANZCTR = Australian New Zealand Clinical Trials Registry number; n refers to the number who were included in the analyses; IU = international unit, RDA = recommended dietary
allowance; Cr = chromium; P = phosphorus; Se = selenium; Mn = manganese; Cu = copper; Zn= zinc; Mg = magnesium; Li = lithium; I = iodine; Ca = calcium; Fe = iron; Si = silicon,
silica; Cl = chloride; Mo = molybdenum; K = potassium; B = boron; V = vanadium; Ni = nickel; Vit A = beta-carotene, retinyl palmitate; Vit C = ascorbate, ascorbic acid; Vit D, D3 =
cholecalciferol; Vit E = d-alpha tocopheryl succinate; B1 = thiamine, B2 = riboflavin; B3 = niacin, nicotinamide; B5 = pantothenic acid, B6 = pyridoxine; B7 = biotin, B9 = folic acid, folate; Vit
H = biotin; EFA = essential fatty acids; ALA = alpha linolenic acid, GLA = gamma linolenic acid; EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; Primary = measure used in
study for participant inclusion criteria, Primary = measure used in study for participant inclusion criteria.
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Based on the meta-analysis, there were statistically and clinically significant improvements on
global functioning on the GAF and the CGAS (MD −3.3, p = 0.001, MID −3.26; SMD −0.49 p = 0.001
MD −0.5); and clinically and statistically significant improvements in clinician-rated CGI-I overall
scores (MD −0.58, p = 0.001, MID -0.5), CGI-I ADHD scores (MD −0.54, p = 0.002, MID −0.5) and the
Clinician-rated ADHD Inattention Change Score (MD -1.53, p = 0.05, MID −0.5). No effect was found
for clinician-rated total ADHD change or hyperactivity scores. No effect was observed for pooled
observer-rated ADHD scores. However, ADHD symptom improvement was clinically and statistically
significant in the study of adults when measured by participant-report (MD −6.71, p = 0.009, estimated
MID −5.4) [34]. See Figure ??.
A post-hoc sensitivity analysis revealed that 21 adults in the Rucklidge et al. 2014 study [26]
met the criteria for moderate depression at baseline (MADRS score >/= 20). Participants in the
micronutrient group demonstrated greater change in symptoms compared to those in the placebo
group: micronutrient group: n = 11, MD = 9.5 standard error (SE) = 2.7; the placebo group: n = 10,
MD = 5.1 SE = 2.0, p = 0.039, effect size (ES) = 0.64.
A third study, Sinn and Bryan, 2007 [41], compared the effects of two groups combined
(a polyunsaturated fatty acids (PUFAs) plus multinutrients group and a PUFA-alone group) to
placebo among 87 children with ADHD (completers’ analyses). Based on the Connors’ Parent and
Teacher Rating Scales, the combined PUFA groups demonstrated significant improvements compared
to placebo on parent ratings of inattention, hyperactivity/impulsivity, and ADHD index scores, but not
teacher-rated scales. However, there were no group differences between the PUFA + multinutrients
group compared with PUFA alone. Multinutrients alone were not compared to placebo. See Table 6.
We rated the overall quality of the evidence base (GRADE) for global/symptomatic improvement
in ADHD to be low. We rated down once for inconsistency as there was considerable variation in the
estimated effect between the different study instruments and raters. We rated down once for imprecision
as the total sample size did not meet the optimal information size, See Table 2. Overall, depending
on the formula used, multinutrients may improve ADHD symptoms based on clinician-rated global
functioning and inattention, and self-report ADHD measures, but not observer-rated measures,
or clinician-rated hyperactivity (Rucklidge et al., 2014 and 2018). In one study [41], insufficient data
were reported to enable exact qualification of multinutrient outcomes.
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Figure 5. Forest plots of meta-analysis of ADHD symptoms.
3.3.6. Autism
Two studies, one in children and adults with autism, Adams et al., 2011 [43] (n = 104), and one
in children with autism, Adams and Holloway, 2004 [42] (n = 20), both three months in duration,
examined a broad-spectrum multinutrient formula containing 29 ingredients, at doses typically higher
than the RDA. See Table 7. Enrollment required a prior diagnosis of autism, pervasive developmental
disorder/not otherwise specified, or Asperger’s syndrome by a psychiatrist or other clinical professional.
Nutrients 2020, 12, 3394 27 of 37








Adams et al., 2011 [41]
NCT01225198
Vit A 1000 IU, Vit C 600 mg, Vit D3
300 IU, Vit E 150 IU, B1 20 mg, B2
20 mg, B3 25 mg, B5 15 mg, B6
40 mg, B9 100 µg, B12 500 µg,
Folinic acid 550 µg, Vit H 150 µg,
Choline 250 mg, Inositol 100 mg,
Mixed carotenoids 3.6 mg,
Coenzyme Q10 50 mg, n-acetyl
cysteine 50 mg, Ca 100 mg, Cr 70
µg, I 100 µg, Li 500 µg, Mg 100 mg,
Mn 3 mg, Mo 150 µg, K 50 mg, Se























Overall (d = 0.46)
Tantrumming (d = 0.51); Receptive
language (d = 0.40)
Hyperactivity (d = 0.37)
Negative: Expressive language,




Vit A (7560, 10,584 IU), B1 (20,
30 mg), B2 (25, 25 mg), B3 (25,
35 mg), B5 (45, 25 mg), B6 (30,
30 mg), B9 (800, 800 µg), B12 (1200,
1600 µg), B7 (100, 150 µg), Choline
(50, 60 mg), Inositol (50, 60 mg), Vit
C (650, 800 mg), Mixed
bioflavonoids (200, 400 mg), Vit D3
(150, 150 IU), Vit E (175, 250 IU), Ca
(175, 200 mg), Ca D-glucarate (0,
75 mg), Cr (75, 100 µg), Mg (175,
200 mg), Mn (3, 3 mg), Mo (0, 75
µg), K (75, 75 mg), Se (70, 85 µg), Si
(0, 3 mg), S (175, 300 mg), Zn (15,
20 mg), N-acetyl cysteine (25,
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B3 = niacin, nicotinamide; B5 = pantothenic acid, B6 = pyridoxine; B7 = biotin, B9 = folic acid, folate; Vit H = biotin; EFA = essential fatty acids; ALA = alpha linolenic acid, GLA = gamma
linolenic acid; EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid.
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Clinical improvement in autism was based on the Parent Global Impressions (PGI)-Revised scales.
Among the 20 children with autism, multinutrients demonstrated a statistically and clinically significant
effect on the PGI sleep subscale (MD = 1.1, p = 0.03, MID −0.5) [42]. Among 104 children and adults
with autism, multinutrients demonstrated a statistically significant (all p-values ≤ 0.02), but not
clinically significant difference on the PGI overall, hyperactivity, tantrumming, and receptive language
subscales, based on the CGI-I MID of 0.5 (MD = 0.33, p < 0.01) [34]. While the studies were adequately
homogenous for pooling, insufficient data were available for meta-analysis. See Table 2.
We rated the overall quality of the evidence base (GRADE) for global impression in autism to
be low. We rated down once due to inconsistency because the effects were not consistent across studies
and populations. We rated down once for imprecision, because we were unable to pool effect estimates
across studies and individual study estimates were imprecise. See Figure 2. Overall, multinutrients
may slightly improve some autism outcomes.
4. Discussion
This paper systematically reviewed the RCT literature using multinutrient formulas containing
vitamins and minerals as treatment for psychiatric symptoms in clinical populations. Sixteen studies
were identified across six clinical areas (depression, post-disaster stress, antisocial personality behaviors,
and behaviors in dementia, ADHD, and autism), with one to three studies within each category,
except for depression, with five studies. Given the heterogeneity of the study formulas, populations,
outcome measures used, and the absence of complete data reporting for both the active and placebo
groups, only the ADHD domain could be meta-analyzed. The overall quality of evidence (GRADE) for
the six areas ranged from very low to low. The limited number and small sample sizes of available
RCT evidence led to down rating for imprecision across all areas. Additional concerns included risk of
bias and inconsistency. Despite signals of important clinical benefit emerging across several of the
studies (based on MID), alongside a substantial literature showing multinutrient benefit based on
experimental methodologies beyond the traditional RCT design [60], the consistency in robust positive
findings for multinutrients based on RCT evidence is lacking. Four key reasons are highlighted for
these inconsistencies, which could be addressed in future studies.
4.1. Populations and Outcomes Studied
One striking finding is how few studies have been conducted using a multinutrient approach with
clinical samples based on the criteria from the Diagnostic and Statistical Manual (DSM). Within this
review, the DSM criteria were used in four studies of MDD, three of ADHD, two of autism and
one of behavioral variants of dementia. Indeed, most studies using a multinutrient approach are
conducted on non-clinical samples [61]. In these populations, given the low symptom levels at baseline,
smaller effects may be observed due to a floor effect, hindering the ability to detect meaningful change.
Another change consideration is the outcome of interest. Given the possible biological effects of
multinutrients (e.g., optimizing neurotransmitter synthesis [62], enabling adenosine triphosphate
(ATP) production [63], altering the microbiome [64], the changes may be more appropriately classified
as “a metabolic tune-up” [65] and reflected in global improvement, rather than treatment of a
particular symptom. For example, in the two ADHD studies where meta-analyses were possible,
the most robust effects were global-the GAF/CGAS ratings: ES = 0.46/0.48; the CGI: ES = 0.57, 0.46.
In contrast, effects were inconsistent for the core ADHD symptoms, depending on the rater. In narrative
synthesis, Adams et al.’s autism study [43] reported a global beneficial effect with a medium effect
size = 0.46 and Pardini [51] showed a significant group difference on change on the CGI-Severity score.
In the prison studies, the reduction in disciplinary incidents may be interpreted as a global “calming”
effect observed as reduced aggression and rule breaking behavior. Aggression also improved in the
child ADHD study [27], as reported by parents and teachers. Future research would benefit from
focusing on the global effect of multinutrients on observable and measurable psychiatric problems,
based on the DSM diagnostic criteria.
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4.2. Dose and Range of the Ingredients
In this paper, we used two terms to refer to the formulas: “multinutrient” for those that met the
inclusion criteria of a combination of at least four vitamins and minerals, typically at or below the RDA
(n = 7) [38,41,44–47,51]; and the term “broad-spectrum multinutrients” (n = 9) [26,27,39,40,42,43,48–50]
to refer to formulas that contained all or most vitamins, plus a range of minerals, at doses typically
at or higher than the RDA. Of the seven studies classified as using a “multinutrient” formula
(Berk [44], Brown [38], Lewis [46], Mech [45], Sarris [47], Pardini [51], and Sinn [41]), one showed
clinically and statistically significant benefit over placebo on the CGI-S [50], based on data provided
in the original papers. In contrast, of the nine studies classified as “broad-spectrum multinutrients”
(Kaplan, Rucklidge [26,27,48,49], Gesch [50], Schoenthaler [40], Zaalberg [39], and Adams [42,43]),
eight reported between-group differences favoring active treatment [26,27,39,40,43,48–50] across a
range of psychiatric symptoms. Figures 2 and 3 illustrate the widely varying range of ingredients, and
their doses, between the formulas.
Two large, well-designed studies for depression [44,47] that reported full data both showed
negative results for depression symptoms, and used targeted nutrients, mainly vitamins. Among the
five depression studies, only four minerals (calcium, zinc, magnesium, selenium) were included in
three of the studies, with levels at or just above the RDA, see Figure 3. The authors concluded that the
“shot gun approach” did not show benefit, and the nutrient combination “may not have been the best”
in terms of the “dose/ratio studied” [47], a sentiment shared by authors of one of the ADHD studies
regarding the multinutrients’ lack of improvement beyond what was shown with PUFA alone [41].
To illustrate the nutrient combinations in depression studies, Figure 4 compares the ingredients and
dosages of the six studies, plus the Rucklidge 2014 study [26] that enrolled adults with ADHD, of which
21 met the criteria for moderate to severe depression based on a MADRS score ≥ 20 at baseline [66].
For ingredient and dose comparison with over-the-counter formulas, the One-A-Day® multivitamin
was shown as well. In comparison to the multinutrient formulas, the broad-spectrum formulas contain
15 essential minerals with doses at or above the RDA. These formulas also include amino acids and
antioxidants. In considering ingredient dosages, it is prudent to remember that the RDA has not been
established for mental health, and higher dosages, though below ULs, may be needed for individuals
experiencing mental health symptoms [29,67].
The doses of two important minerals: magnesium and zinc are compared between formulas
to highlight the dose differences, as illustrated in Figure 6. Magnesium is needed for more than
300 biochemical reactions in the body. It helps maintain normal muscle and nerve function, keeps heart
rhythm regular [68], contributes to bone strength, and assists with oxidative phosphorylation in the
mitochondria [69]. Magnesium is also involved in energy metabolism and protein synthesis [70] and
has been found to reduce central nervous system hyperexcitability in children [71,72].
Equally important, Zinc plays a role in more than 300 enzymatic processes, with many
diverse biochemical roles identified including nucleic acid metabolism, neurotransmitter production,
antioxidant activity, cell signaling, and brain and immune function [73,74]. Mechanisms for improved
mood through zinc supplementation are extensive, including increasing brain-derived neurotrophic
factor [75], gamma amino butyric acid (GABA) [76], and other neurotransmitters, and improving the
integrity of the gastrointestinal tract and epithelial junctures [77]. Zinc also acts as an antioxidant and
plays anti-inflammatory roles [78,79].
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4.3. The Use of Medications
Two of the depression studies, neither of which showed benefit on the primary outcome, included
participants currently taking medications. Both studies were hampered by a large placebo effect [44,47].
Drug–drug interactions can occur when one drug impacts the absorption, transportation, metabolism,
or excretion of another drug (pharmacokinetics). A drug–drug interaction may also occur when
one drug affects how the body responds to another drug (pharmacodynamics), potentially without
changing the second drug’s pharmacokinetics. Constituents in food and dietary supplements can also
significantly change the pharmacokinetics or pharmacodynamics of drugs (e.g., St. John’s Wort and
grapefruit juice inhibiti g and inducing cytochrome P450 3A4 (CYP3A4), respectively) [80].
It is unknown whether a specific multinutrient dietary supplement can impact the
pharmacokinetics of drugs. In theory, a multinutrient supplement could affect the absorption
of a drug, thereby decreasing or increasing its bioavailability. By increasing bioavailability, there is
an increase in total drug exposure that could lead to symptom development. Inversely, by reducing
bioavailability, a previously therapeutic dose may become subtherapeutic due to the decrease in
drug absorbed. Another possible multinutrient-drug interaction could occur at the pharmacodynamic
level, particularly with psychiatric medications.
A multinutrient supplement may ensure that adequate quantities of essential cofactors are
available to synthesize neurotransmitters in the brain, gut, or both. In theory, supplementation
may lead to an increase in neurotransmitter synthesis when adequate quantities of these cofactors,
based on a specific individual’s needs, are not obtained from the diet. An increase in neurotransmitter
synthesis may change how an individual responds to a medication whose mechanism targets the
same neurotransmitter. A meta-analysis of several individual micronutrient supplements, used in
combination with antidepressants, showed improved response to antidepressants, supporting the
potential of pharmacodynamic interactions [19]. A study of adjunctive treatment for psychosis
with multinutrients demonstrated benefit at one-month, continuing up to two years, compared to
patients who took antipsychotics alone [81]. Studies examining the symptom profiles of individuals
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taking multinutrient supplements with medications have observed benefit when reducing medication
dosages after taking a therapeutic dose of the supplement [82]. While several gaps exist in the
mechanistic understanding of combining multinutrient supplements with drugs, observational data
support the need for careful monitoring of therapeutic responses when combining any nutraceutical
with a pharmaceutical to ensure adequate patient response. Supplementation with a multinutrient
formula may require a dose reduction to avoid symptoms due to pharmacodynamic interactions.
The long-term safety of multinutrient use has been observationally studied (n = 35) for up to 12 years
of use (average = 3.75 years (SD = 3.63), with a range of 0.83–12 years), as demonstrated by blood
work and participant responses [83].
4.4. Robustness and Breadth of Methodology
Finally, the quality of the studies, as well as the quality of the results reported, bears comment.
A number of the studies in this review reported results in a format that was not conducive to
meta-analytic analyses. Some studies excluded key between-group comparisons such that clear
determination of a significant group difference was not possible. Many studies included per-protocol
data only, rather than intention to treat. Means and standard deviations, effect sizes, and confidence
intervals were inconsistently reported. These data deficiencies led to unclear and imprecise reporting
of outcomes and resulted in down rating the confidence in the effect estimates. Without these data,
several studies that could have been meta-analyzed, were unable to be compared, leaving a narrative
summary. In some cases, authors reported active intervention benefit without presenting data to
support their finding.
Moving forward, in order to optimize the opportunity to enhance the operation of all metabolic
pathways to improve mental health, study formulas are needed that use the full array of vitamins
and minerals. To allow for possible replication of the global improvement in psychological functioning
observed in several studies, including a measure of global functioning is important. A cost-effectiveness
study would enable the evaluation of a multinutrient approach relative to other treatment methods.
Consideration of optimal study length is also necessary in order to capture treatment effects, if they
do exist. A placebo run-in prior to study initiation may reduce placebo response.
Given the increasing number of people experiencing psychological distress [84], and the
substantial number not benefitting from current treatment approaches, or not utilizing talk
therapies, [85] rigorously exploring alternatives, such as the potential of multinutrients, is important.
Well-powered, well-designed, and well-reported trials are needed to confidently determine whether a
broad-spectrum multinutrient approach is a viable alternative, or complement, to the current psychiatric
treatment regimes.
5. Conclusions
Compared to multinutrient formulas with fewer ingredients delivered at lower doses,
broad-spectrum multinutrients demonstrated more consistent benefits for a range of mental health
issues. Complex B vitamins with minerals showed benefit for symptoms of acute anxiety and stress
post-natural disaster. In order to accurately understand the role of multinutrients for psychiatric
symptoms, studies need to be conducted in populations with mental health issues, using the DSM
criteria, looking at global outcomes. Future studies may build upon these nascent meta-analyses by
reporting full data (between-group effects, confidence intervals, and effect sizes), studying similar
populations, using similar formulas that contain a full range of vitamins and minerals at therapeutic
doses, and the same or related global outcome measures. In studies that include participants using
psychiatric medication, consideration of cross-tapering may improve outcomes.
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Appendix A Details Regarding Search Terms Used
The MeSH terms searched were “micronutri-” or “Micro-nutri-” or “vitamin” or “mineral”
and “Mental disorders” or “Mental processes”. For comprehensiveness, the search was expanded
to include the MeSH terms “Nutritional Physiological Phenomena” and “Mental processes” or
“mental disorders”. To include studies of micronutrient deficiencies, the MeSH term “Deficiency
diseases” was also included. Where MeSH terms were not able to be used, combinations of relevant
search terms were used, with truncation (indicated with an asterisk) used to cover several variations
of search terms (e.g., micronutrient * covers micronutrient and micronutrients). The search terms
for interventions included the most commonly used terms that describe micronutrient interventions.
Terms covering the most common psychiatric illnesses were used and, in line with the broad nature of
the inclusion criteria of this review, the search was broadened to cover affective states and psychological
outcomes. Search terms were “vitamin*” or “mineral*” or “micronutrient*” or “nutrient*” or
“nutrient supplement” and “randomi*” or “trial” or “controlled study” and “mood” or “depression”
or “bipolar*” or “stress” or “anxiety” or “antisocial” or “ADHD” or “autism” or “PDD” or “Asperger
*” or “schizophrenia” or “psychosis” or “alcohol” or “substance use” or “smoking” or “cannabis” or
“bulimia” or “eating disorder” or “anorexia”. Searches were limited to human studies and papers
written or available in English. For example, CENTRAL was searched for (nutr * OR vitamin OR
mineral OR micronutrient) AND (randomi * OR RCT OR placebo * OR double-blind) AND (psych *
OR depressi * OR anxiety OR autism OR bipolar OR ADHD OR schizophrenia OR eating disorders OR
anorexia OR bulimia OR mood OR stress OR antisocial OR aggression OR PDD OR Asperger * OR
psychosis OR alcohol OR dependence OR addiction OR cannabis), with results limited to human trials.
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